Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Earnings

Microbot's LIBERTY robot sales slump 70% quarter on quarter, with negative gross margin

Microbot Medical reported third-quarter revenue of $72,000 and a gross loss, but holds about $62m in cash and has signed Medtechnica as its Israeli distributor.

16 Nov 2026 · Microbot Medical Inc. MBOT · Company news

Microbot Medical's third-quarter sales of its LIBERTY endovascular robotic system came to $72,000, roughly 70% below the $241,000 booked in the second quarter, according to the 10-Q for the period ended 30 September 2026. The company announced the filing on 16 November.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Microbot Medical Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More EarningsAll →